Eli Lilly and Company (LLY) PT Raised to $73.00 at BMO Capital Markets
Eli Lilly and Company (NYSE:LLY) had its price target boosted by stock analysts at BMO Capital Markets from $71.00 to $73.00 in a research note issued to investors on Tuesday. The firm presently has an “underperform” rating on the stock. BMO Capital Markets’ price objective would suggest a potential downside of 15.18% from the company’s previous close.
A number of other equities research analysts have also recently commented on the company. Jefferies Group LLC reiterated a “buy” rating and set a $89.00 target price on shares of Eli Lilly and in a research note on Monday, September 11th. Piper Jaffray Companies reiterated an “overweight” rating and set a $105.00 target price (up from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a research note on Monday, July 17th. Morgan Stanley reiterated a “hold” rating and set a $86.00 target price on shares of Eli Lilly and in a research note on Friday, September 15th. Finally, Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $84.23 to $88.00 in a research note on Tuesday. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and a consensus target price of $88.57.
Shares of Eli Lilly and (NYSE LLY) opened at 86.06 on Tuesday. The company has a market capitalization of $90.79 billion, a price-to-earnings ratio of 37.24 and a beta of 0.34. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $89.09. The firm’s 50-day moving average is $82.97 and its 200 day moving average is $82.18.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same period last year, the business earned $0.86 EPS. The business’s revenue was up 7.8% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and will post $4.16 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Company (LLY) PT Raised to $73.00 at BMO Capital Markets” was published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/10/12/eli-lilly-and-company-lly-pt-raised-to-73-00-at-bmo-capital-markets.html.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 990,000 shares of company stock valued at $82,949,650 in the last ninety days. Insiders own 0.20% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Pathstone Family Office LLC grew its holdings in Eli Lilly and by 100.0% during the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after buying an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. purchased a new position in Eli Lilly and during the 2nd quarter valued at about $494,000. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new position in Eli Lilly and during the 2nd quarter valued at about $128,000. Finally, San Francisco Sentry Investment Group CA purchased a new position in Eli Lilly and during the 2nd quarter valued at about $129,000. 75.72% of the stock is owned by institutional investors and hedge funds.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.